Decheng Capital Management III as of Sept. 30, 2023
Portfolio Holdings for Decheng Capital Management III
Decheng Capital Management III holds 27 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Alpine Immune Sciences | 24.5 | $77M | 6.7M | 11.45 | |
| Zentalis Pharmaceuticals (ZNTL) | 13.5 | $42M | 2.1M | 20.06 | |
| Aura Biosciences (AURA) | 5.8 | $18M | 1.2M | 15.69 | |
| Roivant Sciences Ltd Shs Isin #bmg762791017 (ROIV) | 5.4 | $17M | 1.5M | 11.68 | |
| Acelyrin (SLRN) | 5.0 | $16M | 1.5M | 10.17 | |
| Arcus Biosciences Incorporated (RCUS) | 5.0 | $16M | 870k | 17.95 | |
| 10x Genomics Cl A Com (TXG) | 4.7 | $15M | 360k | 41.25 | |
| Argenx SE SHS (ARGX) | 4.3 | $14M | 27k | 491.63 | |
| I Mab (IMAB) | 4.3 | $13M | 4.2M | 3.20 | |
| Pacific Biosciences of California (PACB) | 3.9 | $12M | 1.5M | 8.35 | |
| Illumina (ILMN) | 3.5 | $11M | 81k | 137.28 | |
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 3.2 | $9.9M | 142k | 69.48 | |
| Horizon Therapeutics | 2.9 | $9.1M | 79k | 115.69 | |
| Phathom Pharmaceuticals (PHAT) | 2.8 | $8.8M | 850k | 10.37 | |
| ImmunoGen | 2.1 | $6.6M | 416k | 15.87 | |
| Seagen | 1.6 | $4.9M | 23k | 212.15 | |
| Cue Health (HLTHQ) | 1.3 | $4.0M | 9.0M | 0.44 | |
| BeyondSpring SHS (BYSI) | 1.3 | $4.0M | 5.0M | 0.80 | |
| Terns Pharmaceuticals (TERN) | 1.1 | $3.6M | 714k | 5.03 | |
| Equillium (EQ) | 1.1 | $3.3M | 4.4M | 0.74 | |
| Aadi Bioscience (AADI) | 0.8 | $2.5M | 526k | 4.84 | |
| AtriCure (ATRC) | 0.6 | $2.0M | 46k | 43.80 | |
| Scynexis Com New (SCYX) | 0.4 | $1.3M | 556k | 2.28 | |
| Mersana Therapeutics (MRSN) | 0.4 | $1.1M | 904k | 1.27 | |
| Pyxis Oncology (PYXS) | 0.2 | $650k | 327k | 1.99 | |
| GeneDx Holdings Corp. Com Cl A (WGS) | 0.1 | $377k | 104k | 3.64 | |
| Adicet Bio (ACET) | 0.1 | $274k | 200k | 1.37 |
